Non-Small Cell Lung Cancer (NSCLC)

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

This video segment explores emerging investigational agents for the management of metastatic ALK-positive NSCLC, highlighting promising advancements in the treatment landscape.

This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.

“We have huge amounts of work to do to maximize the efficacy of immunotherapy,” Christine Bestvina, MD, said during an interview with CancerNetwork.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Christine Bestvina, MD, stated that the presence of EGFR and ALK mutations can affect the way that a patient will react to treatment and should be factors that physicians consider.

6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.

“We need some longer-term overall survival data to help discuss with patients the best treatment of choice for them,” Christine Bestvina, MD, said.

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.

This video segment reviews the clinical evidence supporting lorlatinib as a first-line treatment for ALK-positive metastatic NSCLC, emphasizing key efficacy outcomes from the phase 3 CROWN trial.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Dr. Garon discusses his approach to selecting between available EGFR inhibitors for treating EGFR+ NSCLC.

Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.

Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

Referring to the NCCN guidelines for the treatment of EGFR-mutated NSCLC will help clinicians determine which treatments are best recommended.

The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.

The NeXT Personal platform identified minuscule amounts of ctDNA that were found to be predictive of OS and RFS outcomes in patients with lung adenocarcinoma.

The FDA accepted a BLA for Dato-DXd based on data from the TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01 trials.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.